For glioma molecular classification and prognostication, various molecular abnormalities have received considerable attention, including IDH1/2 mutations, ATRX mutations, 1p/19q co‐deletion, TERT promoter mutations, and MGMT promoter methylation.6 This evidence concerns the gene IDH1 and glioma.